<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>GIAZO- balsalazide disodium tablet, film coated </strong><br>Salix Pharmaceuticals, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer"><span class="Bold">These highlights do not include all the information needed to use GIAZO safely and effectively. See full prescribing information for GIAZO. <br><br>GIAZO (balsalazide disodium) tablets, for oral use<br>Initial U.S. Approval: 2000</span></div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">GIAZOis a locally acting aminosalicylate indicated for the treatment of mildly to moderately active <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> in male patients 18 years of age and older. (<a href="#LINK_5abee4f8-5abc-4c74-b1ee-75dddee4285c">1</a>) </p>
<p class="Highlighta"><span class="Underline">Limitations of Use</span> </p>
<ul class="Disk">
<li>Effectiveness in female patients was not demonstrated in clinical trials. <a href="#LINK_5abee4f8-5abc-4c74-b1ee-75dddee4285c">(1)</a>  
</li>
<li>Safety and effectiveness of GIAZO beyond 8 weeks have not been established. (<a href="#LINK_5abee4f8-5abc-4c74-b1ee-75dddee4285c">1</a>) </li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">Three 1.1 g GIAZOtablets 2 times a day (6.6 g/day) with or without food for up to 8 weeks. <a href="#LINK_5e9e04e1-d901-4d53-844e-987124fa7cdf">(2)</a>  </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets: 1.1 g (<a href="#LINK_b8b0a298-808e-4ec0-8ed0-d1625934034f">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Patients with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to salicylates or to any of the components of GIAZO tablets or balsalazide metabolites. (<a href="#LINK_85926bc9-a660-4f45-8a82-e756f1b52d8c">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disk">
<li>Exacerbation of the symptoms of <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> was reported.  Observe patients closely for worsening of these symptoms while on treatment. (<a href="#LINK_96b3348b-6784-4f6f-a20a-d8e258864fe8">5.1</a>) 
</li>
<li><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span> may occur.  Assess renal function at the beginning of treatment and periodically during treatment. <a href="#LINK_e988f0c4-f2ab-454e-b954-23f0175adfac">(5.2)</a>  
</li>
<li><p class="Highlighta">Use with caution with pre-existing liver disease. <a href="#LINK_e988f0c4-f2ab-454e-b954-23f0175adfac">(5.3)</a>  </p></li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (incidence ≥2%) in male UC patients are  <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>. (<a href="#LINK_dc68d2a0-0dfe-4205-8312-42d98aeed871">6.1</a>). </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals, Inc. at 1-800-508-0024 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 4/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Exacerbations of <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">Ulcerative Colitis</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Use in <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL TRIALS</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">Ulcerative Colitis</span></a></h2>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_5abee4f8-5abc-4c74-b1ee-75dddee4285c"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">GIAZO is indicated for the treatment of mildly to moderately active <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> in male patients 18 years of age and older.</p>
<p><span class="Underline">Limitations of Use: </span></p>
<ul class="Disk">
<li>Effectiveness of GIAZO in the treatment of female patients was not demonstrated in clinical trials <span class="Italics">(see Clinical Trials (<a href="#LINK_07335d3d-aa81-4d42-95db-c00ae727c9e2">14.1</a>)].</span>  </li>
<li>Safety and effectiveness of GIAZO therapybeyond 8 weeks have not been established. </li>
</ul>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_5e9e04e1-d901-4d53-844e-987124fa7cdf"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">The dose is three 1.1 g GIAZO tablets to be taken 2 times a day with or without food (6.6 g per day) for up to 8 weeks. </p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="LINK_b8b0a298-808e-4ec0-8ed0-d1625934034f"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">GIAZO is available as yellow, oval, film-coated tablets containing 1.1 g balsalazide disodium, with BZT debossed on one side of the tablet.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_85926bc9-a660-4f45-8a82-e756f1b52d8c"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">GIAZO is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to salicylates, aminosalicylates or their metabolites, or to any of the components of GIAZO tablets<span class="Italics"> [see Description </span><span class="Italics"><a href="#LINK_361b896d-1bbb-460f-8d39-65e8ced34b17">(11)</a></span><span class="Italics">].</span></p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_e988f0c4-f2ab-454e-b954-23f0175adfac"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_96b3348b-6784-4f6f-a20a-d8e258864fe8"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Exacerbations of <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">Ulcerative Colitis</span></h2>
<p class="First">Balsalazide is converted to mesalamine, which has been associated with an acute intolerance syndrome that may be difficult to distinguish from an exacerbation of <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>.  In controlled clinical trials with GIAZO in adults with <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, 7% of male patients reported exacerbation of the symptoms of <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>.  Symptoms include cramping, acute <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> and <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span>, sometimes <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.  Observe patients closely for worsening of these symptoms while on treatment. If acute intolerance syndrome is suspected, promptly discontinue treatment with GIAZO. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_aa162ee4-25f8-4558-8dd2-9016d60bf097"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>, including minimal change <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">nephropathy</span>, acute and <span class="product-label-link" type="condition" conceptid="4177206" conceptname="Tubulointerstitial nephritis">chronic interstitial nephritis</span> and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, has been reported in patients given products that release mesalamine in the gastrointestinal tract.  Evaluate renal function prior to initiation of GIAZO therapy and periodically while on therapy.  Exercise caution when using GIAZO in patients with known renal dysfunction or a history of <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>.  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_fc235257-fdf3-4da5-b463-05d3e8c3fdf0"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Use in <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">There have been reports of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> in patients with pre-existing liver disease who have been administered mesalamine.  Because balsalazide is converted to mesalamine, use caution and consider liver function testing when administering GIAZO to patients with liver disease.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_4010a6e4-ea71-4c51-864c-167241780b72"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_dc68d2a0-0dfe-4205-8312-42d98aeed871"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The data described below reflect exposure of GIAZO in 565 <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> patients with mildly to moderately active disease.  GIAZO was evaluated in one placebo-controlled trial (168 treated with GIAZO), one active-controlled trial (210 treated with GIAZO); and a subset of these patients also participated in an uncontrolled, open-label, extension study (additional 187 treated with GIAZO).  The population studied had a mean age of 43.1 (range: 18-80) years; approximately 94% of patients were &lt; 65 years old, 49% were male, and 84% were white.</p>
<p>In the placebo-controlled trial, the most common adverse reactions with GIAZO in male patients were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>.  10% of patients in the GIAZO group and 13% of patients in the placebo group discontinued treatment due to an adverse reaction.  The majority of adverse reactions were mild to moderate in severity. The most common serious adverse reactions in both the placebo and GIAZO groups were <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorders</span>, which were mainly associated with symptoms of <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>.</p>
<p>Adverse reactions occurring in at least 2% of male patients and at a rate numerically higher than placebo in the placebo-controlled trial are listed in Table 1.  </p>
<p><span class="Bold">Table 1: Adverse Reactions Experienced by at Least 2% of GIAZO –Treated Male Patients and at a Rate Numerically Greater than Placebo in a Placebo-Controlled Trial</span></p>
<table>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="bottom"><p class="First"><span class="Bold">Adverse Reaction</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">GIAZO6.6 g/day</span></p>
<p><span class="Bold">N=82</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">PLACEBO</span></p>
<p><span class="Bold">N=37</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3.7%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3.7%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3.7%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3.7%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.4%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.4%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">Musculoskeletal Pain</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.4%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0%</p></td>
</tr>
</tbody>
</table>
<p>Data collected from all three trials (placebo-controlled, active-controlled, and open-label) showed that female patients reported adverse reactions more frequently than did male patients (76% and 66%, respectively).</p>
<p>The following adverse reactions, presented by body system, were reported by less than 1% of GIAZO-treated <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> patients in controlled trials. </p>
<p><span class="Underline">Cardiovascular and Vascular</span>: <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">increased blood pressure</span>, increased heart rate</p>
<p><span class="Underline">Dermatological</span>: <span class="product-label-link" type="condition" conceptid="140176" conceptname="Erythema nodosum">erythema nodosum</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></p>
<p><span class="Underline">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span></p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4216708" conceptname="Urgent desire for stool">defecation urgency</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, hard feces, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux disease</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> </p>
<p><span class="Underline">Hepatobiliary Disorders</span>: increased <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> </p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></span>: <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span></p>
<p><span class="Underline">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span></p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span></p>
<p><span class="Underline">General Disorders and Administrative Site Disorders</span>: face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_66bad13b-1efc-48b5-9a25-3b885db5bf11"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">Because these reactions are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These adverse reactions have been chosen for inclusion due to a combination of seriousness, frequency of reporting, or potential causal connection to products which contain or are metabolized to mesalamine, including balsalazide. </p>
<p><span class="Underline">Cardiovascular and Vascular</span>: <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span>, <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span></p>
<p><span class="Underline">Respiratory</span>: alveolitis, <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (with and without <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>)</p>
<p><span class="Underline">Gastrointestinal</span>: <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span></p>
<p><span class="Underline">Renal</span>: interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>.</p>
<p><span class="Underline">Hepatobiliary Disorders: </span>elevated liver enzymes (AST, ALT, GGT, LDH, alkaline phosphatase), elevated bilirubin, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>, cirrhosis, <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">hepatocellular damage</span> including <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">liver necrosis</span> and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>, Kawasaki-like syndrome including hepatic dysfunction.  Some of these cases were fatal.</p>
<p><span class="Underline">Dermatological</span>: <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_bf6e0298-6373-4acf-be6e-493f95a653a4"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Based on <span class="Italics">in vitro</span> studies, balsalazide and its metabolites [5‑aminosalicylic acid (5-ASA), N-acetyl-5-aminosalicylic acid (N-Ac-5-ASA), 4‑aminobenzoyl-ß-alanine (4-ABA), and N-acetyl-4-aminobenzoyl-ß-alanine (N‑Ac‑4‑ABA)] are not expected to inhibit the metabolism of other drugs that are substrates of CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4/5.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="LINK_36cf5b89-52f2-4c8a-9c9c-01a2dd065b84"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_4c2c1690-6ad5-4a37-be27-27e4fbc1ed9e"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category B.  Reproduction studies were performed in rats and rabbits at oral doses up to 2 g/kg/day, 2.5 and 4.9 times the recommended human dose based on body surface area for the rat and rabbit, respectively, and revealed no evidence of impaired fertility or harm to the fetus due to balsalazide disodium.  There are, however, no adequate and well-controlled studies in pregnant women.  Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
<p>Mesalamine, a metabolite of GIAZO, is known to cross the placental barrier.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_0a4bb663-7184-45b9-b151-52f03c80c2bc"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether balsalazide disodium or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when GIAZOis administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_385b171f-45a2-44e7-87bb-d310ed6127ff"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness of GIAZO in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2636672f-e648-4b1f-8576-416c4046e14f"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Reports from uncontrolled clinical studies and postmarketing reporting systems suggested a higher incidence of <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span>, i.e., <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span> in patients who were 65 years or older who were taking mesalamine-containing products. GIAZO is converted into mesalamine in the colon. Caution should be taken to closely monitor blood cell counts during therapy. </p>
<p>Clinical trials of GIAZO did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects.  Other reported clinical experience has not identified differences in responses between elderly and younger patients.  In general, the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy in elderly patients should be considered when prescribing GIAZO.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_8d9aeb5c-b06e-4b65-8c5a-9efa0619cb75"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">No case of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> has been reported with GIAZO.  GIAZO is an aminosalicylate, and symptoms of salicylate toxicity include: <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>, <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span>, <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperpnea</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>.  Severe <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> may lead to electrolyte and blood pH imbalance and potentially to other organ (e.g., renal and liver) involvement.  There is no specific antidote for balsalazide <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.  Proper medical care should be sought immediately with appropriate supportive care, including the possible use of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, cathartics, and activated charcoal to prevent further absorption.  </p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_361b896d-1bbb-460f-8d39-65e8ced34b17"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Each GIAZOtablet contains 1.1 g of balsalazide disodium, an orally available prodrug that is enzymatically cleaved to produce mesalamine (5‑aminosalicylic acid, 5‑ASA), an anti-inflammatory drug.  Balsalazide disodium has the chemical name (E)-5-[[-4-[[(2-carboxyethyl) amino]carbonyl] phenyl]azo]-2-hydroxybenzoic acid, disodium salt, dihydrate.  Its structural formula is: </p>
<div class="Figure">
<img alt="structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fc5146c6-448b-44c9-bb06-8bdfe484f2f1&amp;name=giazo-1.jpg"><p class="MultiMediaCaption"></p>
</div>
<p>Molecular Weight: 437.32</p>
<p>Molecular Formula: C<span class="Sub">17</span>H<span class="Sub">13</span>N<span class="Sub">3</span>O<span class="Sub">6</span>Na<span class="Sub">2</span>•2H<span class="Sub">2</span>O</p>
<p>Balsalazide disodium is a stable, odorless, orange to yellow, microcrystalline powder.  It is insoluble in acid, but soluble at a pH of at least 4.5. It is freely soluble in water and isotonic saline, sparingly soluble in methanol and ethanol, and practically insoluble in all other organic solvents.  </p>
<p>Inactive Ingredients: Each tablet contains hypromellose, magnesium stearate, and Opadry II Yellow.  The sodium content of each tablet is approximately 126 mg.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_69061944-d16d-4989-bc51-c3be38876ecd"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="LINK_c929ff5b-6d66-45bf-92bd-0b2fe9455f3d"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Balsalazide is a prodrug of mesalamine (5-aminosalicylic acid, 5-ASA).  The mechanism of action of 5-ASA is unknown, but appears to be local to the colonic mucosa rather than systemic.  Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase pathways, i.e., prostanoids, and through the lipoxygenase pathways, i.e., leukotrienes and hydroxyeicosatetraenoic acids, is increased in patients with <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, and it is possible that 5-ASA diminishes <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> by blocking production of arachidonic acid metabolites in the colon.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_e4eae94c-a7bd-4dfd-87c4-067600bf1fbf"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Following oral administration, balsalazide is cleaved by azoreductases produced by anaerobic bacteria found in the gut, to release equimolar quantities of 5-ASA, the active moiety, and 4‑aminobenzoyl‑ß‑alanine (4-ABA), a carrier moiety.  Both of these moieties are N‑acetylated to form N-Ac-5-ASA and N-Ac-4-ABA, respectively.</p>
<p><span class="Italics">Absorption</span></p>
<p>After single-dose administration of 3.3 g GIAZO in 18 healthy subjects, the median time of peak plasma concentration (T<span class="Sub">max</span>) was 0.5 hr for balsalazide, while the median T<span class="Sub">max </span>was 12 hr for both 5-ASA and N-Ac-5-ASA (Table 2).  Pharmacokinetic parameters exhibited high variability, with %CV ranging from 31% to 67% for AUC and from 27% to 68% for C<span class="Sub">max</span>.</p>
<p>Pharmacokinetics were also estimated in healthy volunteers after repeated doses of 3.3 g GIAZO tablets every 12 hours for 7 days.  After multiple doses, steady-state was achieved after about 3 days for balsalazide and all metabolites.  The AUC and C<span class="Sub">max</span> were the highest for N‑Ac-5-ASA, followed by 5-ASA and balsalazide.  There was minimal accumulation of balsalazide, as suggested by a 1.2-fold increase in AUC; however, a relatively larger increase in the systemic exposure to metabolites was observed at steady-state.  The accumulation ratios based on AUC for the metabolites were 6.1 for 5-ASA, 3.6 for N-Ac-5-ASA, 4.8 for 4‑ABA, and 3.6 for N-Ac-4-ABA.</p>
<p><span class="Bold">Table </span><span class="Bold">2: Pharmacokinetic Parameters for Balsalazide and Metabolites (5-ASA and N‑Ac-5-ASA) Following Single- and Repeated-Doses (Q12) of 3.3 g Balsalazide Disodium as GIAZO (N=18)</span></p>
<table>
<col>
<col>
<col>
<col>
<col>
<thead>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="top"><p class="First"><span class="Bold"> </span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Single Dose</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Repeated Dose</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="bottom"><p class="First"><span class="Bold">Parameter</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Mean</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">SD</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Mean</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">SD</span></p></td>
</tr>
</thead>
<tbody>
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="6" valign="top"><p class="First"><span class="Bold">C<span class="Sub">max</span> (mcg/mL)</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="top"><p class="First">Balsalazide</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0.2</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">0.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="top"><p class="First">5-ASA</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0.3</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">1.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="top"><p class="First">N-Ac-5-ASA</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0.4</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">2.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0.6</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="6" valign="top"><p class="First"><span class="Bold">T<span class="Sub">max</span><span class="Sup">a</span> (hours)</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="top"><p class="First">Balsalazide</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">(0.5-2)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">0.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">(0.5-2)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="top"><p class="First">5-ASA</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">(8-16)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">(1.5-16)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="top"><p class="First">N-Ac-5-ASA</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">(8-16)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">(1-16)</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="6" valign="top"><p class="First"><span class="Bold">AUC<span class="Sub">tau</span> (mcg</span>•<span class="Bold">h/mL)</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="top"><p class="First">Balsalazide</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0.7</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">1.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0.9</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="top"><p class="First">5-ASA</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1.6</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">13.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="top"><p class="First">N-Ac-5-ASA</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5.9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2.9</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">21</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6.4</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="6" valign="top"><p class="First"><span class="Bold">AUC<span class="Sub">0‑∞</span> (mcg</span>•<span class="Bold">h/mL)</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Balsalazide</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><p class="First">1.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0.8</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">NA</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">NA</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">5-ASA</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><p class="First">8.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.9</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">NA</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">NA</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">N-Ac-5-ASA</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><p class="First">33.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">14.1</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">NA</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">NA</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="6" valign="top"><p class="First"><span class="Bold">T</span><span class="Bold"><span class="Sub">½</span></span><span class="Bold"><span class="Sup">b</span></span><span class="Bold"> (hour)</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Balsalazide</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><p class="First">1.9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0.7</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">8.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">12.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">5-ASA</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><p class="First">9.5<span class="Sup">b</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10.1</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">9.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">N-Ac-5-ASA</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><p class="First">10.4<span class="Sup">b</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">17.6</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">7.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6.8</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="6"><p class="First">a    Expressed as median and range.</p></td></tr>
<tr class="Last"><td class="Botrule Lrule Rrule Toprule" colspan="6"><p class="First">b    N=17</p></td></tr>
</tbody>
</table>
<p><span class="Italics">Food effect</span></p>
<p>After administration of single dose of 3.3 g (3 × 1.1 g tablets) of GIAZO with a high-fat meal in healthy volunteers, the AUC of balsalazide was unaffected compared to fasted administration, but the presence of food reduced both peak concentrations and AUC of the metabolites 5-ASA and N-Ac-5-ASA.  A high fat meal increased the median T<span class="Sub">max </span>for balsalazide from 0.5 to 2 hours; for 5‑ASA from 12 to 24 hours; and for N-Ac-5-ASA from 12 to 24 hours.  Under fed conditions, the mean C<span class="Sub">max</span> was reduced by 44% for balsalazide, 65% for 5‑ASA, and 48% for N-Ac-5-ASA.  No significant changes were observed for AUC<span class="Sub">0‑∞</span> for balsalazide; however, AUC<span class="Sub">0‑∞</span> was reduced for 5-ASA by 46% and for N-Ac-5-ASA by 17%.</p>
<p><span class="Italics">Distribution</span></p>
<p>The binding of balsalazide to human plasma proteins was ≥ 99%; 5-ASA and N-Ac-5-ASA were 43% and 78% bound, respectively, to plasma proteins.</p>
<p><span class="Italics">Metabolism and Excretion</span></p>
<p>Following oral administration, balsalazide is cleaved by bacterial azoreduction to release equimolar quantities of 5-ASA, the active moiety, and 4-ABA, a carrier moiety.  Mesalamine (5-ASA) and 4-ABA are further acetylated to N-Ac-5-ASA and N-Ac-4-ABA, respectively in the intestinal mucosa and liver.  The terminal half-life was 1.9 h for balsalazide, 9.5 h for 5-ASA, and 10.5 h for N-Ac-5-ASA.</p>
<p>At steady-state following administration of repeated doses of 3.3 g GIAZO every 12 hours in healthy volunteers, the combined % of dose excreted in urine for balsalazide and its metabolites over 12 hours was 23%.  The mean % of dose excreted in urine over 12 hours was 0.16% for balsalazide, 4.6% for 5-ASA, 15.6% for N-Ac-5-ASA, 0.40% for 4-ABA, and 1.8% for N-Ac-4-ABA.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="LINK_0388db6a-0e27-43c1-9bb9-6ab7d1e348e3"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_c8438dec-60a3-4c18-8e5b-e38570167db7"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">In a 24-month rat (Sprague Dawley) carcinogenicity study, oral (dietary) balsalazide disodium at doses up to 2 g/kg/day was not tumorigenic.  For a 50 kg person of average height this dose represents 2.5 times the recommended human dose on a body surface area basis.  Balsalazide disodium was not genotoxic in the following <span class="Italics">in vitro</span> or <span class="Italics">in vivo</span> tests: Ames test, human lymphocyte chromosomal aberration test, and mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cell (L5178Y/TK+/-) forward mutation test, or mouse micronucleus test.  However, it was genotoxic in the <span class="Italics">in vitro</span> Chinese hamster lung cell (CH V79/HGPRT) forward mutation test. </p>
<p>The compound 4‑aminobenzoyl‑ß‑alanine, a metabolite of balsalazide disodium, was not genotoxic in the Ames test and the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cell (L5178Y/TK+/-) forward mutation test but was positive in the human lymphocyte chromosomal aberration test.  N-acetyl-4-aminobenzoyl-ß-alanine, a conjugated metabolite of balsalazide disodium, was not genotoxic in Ames test, the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cell (L5178Y/TK+/-) forward mutation test, or the human lymphocyte chromosomal aberration test.  Balsalazide disodium at oral doses up to 2 g/kg/day, 2.5 times the recommended human dose based on body surface area, was found to have no effect on fertility and reproductive performance in rats.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="LINK_c8c86ec1-fb0b-45dd-9fd0-a3057ceeecaa"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL TRIALS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_07335d3d-aa81-4d42-95db-c00ae727c9e2"></a><a name="section-13.1"></a><p></p>
<h2>14.1 <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">Ulcerative Colitis</span></h2>
<p class="First">A double-blind, placebo-controlled, multi-center trial was conducted in 250 adult patients with mildly to moderately active <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>.  The trial population was primarily white (84%), had a mean age of 44 years (7% age 65 years or older), and 49% were men.  Disease activity was assessed using a modified Mayo Disease Activity Index<span class="Sup">1</span> (MMDAI), which was a sum of four subscores (bowel frequency, <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal bleeding</span>, endoscopic appearance, and physician’s global assessment), each ranging from 0 to 3, with higher scores indicating worse disease.  The median baseline MMDAI score was 8 and the median baseline <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal bleeding</span> subscore was 2.  Patients were randomized 2:1 to receive 8 weeks of treatment with either GIAZO 3.3 g twice daily or placebo.  </p>
<p>The primary efficacy endpoint was the proportion of patients that achieved clinical improvement and improvement in the <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal bleeding</span> subscale of the MMDAI at the end of 8 weeks of treatment.  Clinical Improvement was defined as having both a ≥ 3 point improvement from baseline in the MMDAI score and a ≥ 1 point improvement from baseline in the <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal bleeding</span> subscore.  Two key secondary efficacy endpoints were the proportion of patients with Clinical Remission and Mucosal Healing at the end of 8 weeks of treatment. Clinical Remission was defined as a score of 0 for <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal bleeding</span> and a combined score of ≤ 2 for bowel frequency and physician’s assessment using the MMDAI subscale; the endoscopic sub-score was not considered in this definition.  Mucosal Healing was defined as an endoscopy/sigmoidoscopy score of 0 or 1, where a score of 1 could include signs of <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> or decreased vascular pattern; by definition, the presence of friability indicated a score of 2 or 3.</p>
<p>After 8 weeks of treatment, the proportion of patients who met the definition of Clinical Improvement was greater for the GIAZO-treated group compared to the placebo group (Table 3).</p>
<p><span class="Bold">Table 3: Proportion of Patients with Clinical Improvement* at Week 8</span></p>
<p><span class="Bold">for the Total Population and by Gender Subgroups</span></p>
<table border="0" cellpadding="0" cellspacing="0">
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td><p class="First"><span class="Bold">GIAZO</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Placebo</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">p-value</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Total Population</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">55%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">40%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0.0237</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">Males</p>
<p>Females</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">57%</p>
<p>54%</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">20%</p>
<p>58%</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
</tr>
</tbody>
</table>
<p>*  Clinical Improvement: ≥ 3 improvement in MMDAI score and ≥ 1 point improvement in <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal bleeding</span>.</p>
<p>These differences were statistically significant in the overall population; however, these effects were entirely driven by the results in the male subpopulation.  With adjustment for multiplicity, statistically significant differences were also seen in the male patients for Clinical Remission (35% with GIAZO vs. 13% for placebo) and for Mucosal Healing (52% with GIAZO vs. 20% for placebo).  Effectiveness of GIAZO was not demonstrated in the female subpopulation in the clinical trial.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="LINK_c7ab52a2-ba3b-48de-868c-90309fe1fa22"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<p class="First">1.   Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mild to moderately active <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>: a randomized study.  N Engl J Med. 1987;317:1625-9.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_25bd1dd6-b5cd-49de-ac5f-1cf5740db5c0"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First"><span class="Italics">How Supplied</span></p>
<p>GIAZO is available as oval, yellow, film-coated tablets containing 1.1 g balsalazide disodium, with BZT debossed on one side of the tablet.</p>
<p>NDC 65649-102-02 Bottles of 180 tablets</p>
<p><span class="Italics">Storage</span></p>
<p>Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° and 30°C (59° and 86°F). See USP Controlled Room Temperature.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_2982d92d-ab2b-4ed7-aca2-7e7b0caf6067"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<ul class="Disk">
<li>Instruct patients not to take GIAZO if they have a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to salicylates (e.g., aspirin).</li>
<li>Instruct patients to take GIAZO with or without food.</li>
<li>Advise patients who need to control sodium intake that the recommended dosing of GIAZO (6.6 g/day) provides about 756 mg of sodium per day.</li>
<li>Instruct patients to contact their health care provider if they experience a worsening of their <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> symptoms, because it could be due to a reaction to GIAZO.</li>
<li>Instruct patients to make sure they let their health care provider know:<ul class="Circle">
<li>If they have or are later diagnosed with renal dysfunction. Damage to the kidney has been observed in some people given medications similar to GIAZO.</li>
<li>If they have or are later diagnosed with liver disease. Worsening liver disease has been observed in some people given medications similar to GIAZO.</li>
</ul>
</li>
</ul>
<p class="First">Manufactured by:</p>
<p>Nexgen Pharma, Inc. </p>
<p>Manufactured for:</p>
<div class="Figure">
<img alt="salix-logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fc5146c6-448b-44c9-bb06-8bdfe484f2f1&amp;name=giazo-2.jpg"><p class="MultiMediaCaption"></p>
</div>
<p>Salix Pharmaceuticals, Inc.</p>
<p>Raleigh, NC 27615</p>
<p>GIAZO is a trademark of Salix Pharmaceuticals, Inc.</p>
<p>U.S. Patent Nos. 6,197,341; 7,452,872; and 7,625,884</p>
<p>Please see <a href="#www.salix.com">www.salix.com</a> for patent information. </p>
<p>VENART-090-0 / JUN 2012</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_7aadc228-fba3-4536-bb5a-32edc835be1d"></a><a name="section-17"></a><p></p>
<h1>PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - Giazo 180 Tablets, Bottle Label</h1>
<p class="First"> <span class="Bold">NDC</span> 65649-102-02</p>
<p><span class="Bold">GIAZO 1.1 g<br></span>(balsalazide disodium)</p>
<p>180 Tablets<br>Rx Only</p>
<p>Salix Pharmaceuticals, Inc.</p>
<p><img alt="180-count-label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fc5146c6-448b-44c9-bb06-8bdfe484f2f1&amp;name=giazo-3.jpg"><p class="MultiMediaCaptionNotCentered"></p> </p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>GIAZO 		
					</strong><br><span class="contentTableReg">balsalazide disodium tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:65649-102</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>BALSALAZIDE DISODIUM</strong> (BALSALAZIDE) </td>
<td class="formItem">BALSALAZIDE DISODIUM</td>
<td class="formItem">1.1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">BZT</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:65649-102-02</td>
<td class="formItem">180  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022205</td>
<td class="formItem">02/02/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Salix Pharmaceuticals, Inc.
							(793108036)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 5/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>f3376152-74a9-40f0-9301-793c5017ef87</div>
<div>Set id: fc5146c6-448b-44c9-bb06-8bdfe484f2f1</div>
<div>Version: 8</div>
<div>Effective Time: 20130513</div>
</div>
</div> <div class="DistributorName">Salix Pharmaceuticals, Inc.</div></p>
</body></html>
